Literature DB >> 17889485

In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea.

Joaquim Ruiz1, Laura Mensa, Cristina O'Callaghan, Maria J Pons, Ana González, Jordi Vila, Joaquim Gascón.   

Abstract

The in vitro activity of rifaximin against 84 diarrheagenic Escherichia coli and 11 Shigella sonnei causing traveler's diarrhea was evaluated. The MIC of rifaximin ranged between <0.007 and 32 mg/L; other agents tested had an MIC of >256 mg/L in most cases. The results showed the potential use of rifaximin to treat these infections.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17889485     DOI： 10.1016/j.diagmicrobio.2007.07.003

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  13 in total

1.  Comparative analysis of antimicrobial resistance in enterotoxigenic Escherichia coli isolates from two paediatric cohort studies in Lima, Peru.

Authors:  Anicia M Medina; Fulton P Rivera; Maria J Pons; Maribel Riveros; Cláudia Gomes; María Bernal; Rina Meza; Ryan C Maves; Luis Huicho; Elsa Chea-Woo; Claudio F Lanata; Ana I Gil; Theresa J Ochoa; Joaquim Ruiz
Journal:  Trans R Soc Trop Med Hyg       Date:  2015-08       Impact factor: 2.184

Review 2.  Pathogen-induced secretory diarrhea and its prevention.

Authors:  S Anand; S Mandal; P Patil; S K Tomar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-29       Impact factor: 3.267

3.  Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain.

Authors:  Martina Bielaszewska; Evgeny A Idelevich; Wenlan Zhang; Andreas Bauwens; Frieder Schaumburg; Alexander Mellmann; Georg Peters; Helge Karch
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

4.  Rifaximin for the treatment of acute infectious diarrhea.

Authors:  Kyoung Sup Hong; Joo Sung Kim
Journal:  Therap Adv Gastroenterol       Date:  2011-07       Impact factor: 4.409

5.  Bile acids improve the antimicrobial effect of rifaximin.

Authors:  Charles Darkoh; Lenard M Lichtenberger; Nadim Ajami; Elizabeth J Dial; Zhi-Dong Jiang; Herbert L DuPont
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

6.  Emergence of Resistance to Quinolones and β-Lactam Antibiotics in Enteroaggregative and Enterotoxigenic Escherichia coli Causing Traveler's Diarrhea.

Authors:  Elisabet Guiral; Milene Gonçalves Quiles; Laura Muñoz; Javier Moreno-Morales; Izaskun Alejo-Cancho; Pilar Salvador; Miriam J Alvarez-Martinez; Francesc Marco; Jordi Vila
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

7.  In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.

Authors:  David J Farrell; Shannon D Putnam; Douglas J Biedenbach; Luigi Moro; Roberta Bozzella; Giuseppe Celasco; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-12-13       Impact factor: 5.191

Review 8.  Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.

Authors:  Hoonmo L Koo; Herbert L DuPont
Journal:  Curr Opin Gastroenterol       Date:  2010-01       Impact factor: 3.287

9.  The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.

Authors:  Hoonmo L Koo; Herbert L Dupont; David B Huang
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

10.  Summary of the Committee to Advise on Tropical Medicine and Travel (CATMAT) Statement on Travellers' Diarrhea.

Authors:  M Libman
Journal:  Can Commun Dis Rep       Date:  2015-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.